[National medical protocols and associated prescriptions, updated in August 2020: administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care]
Record ID 32018000863
Original Title: Protocoles médicaux nationaux et ordonnances associées (mise à jour août 2020): administration des médicaments prescrits dans le cadre d’une ordonnance individuelle en cas de détresse chez une personne qui reçoit des soins palliatifs
Authors' objectives: The Ministère de la Santé et des Services sociaux (MSSS) has tasked the Institut national d’excellence en santé et en services sociaux (INESSS) with developing, updating and hosting the current national medical protocols and prescription templates. Following a prioritization exercise, the MSSS’s Direction nationale des soins et services infirmiers asked INESSS to update the current version of the national medical protocol (NMP) on the administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care. This protocol expired in April 2020.
Authors' results and conclusions: RESULTS: The information search yielded 1,182 items, none of which contained clinical practice recommendations on the administration details for the benzodiazepine-opioid-anticholinergic trio for treating distress in a palliative care patient. However, three clinical practice guidelines did contain clinical information on the signs and symptoms associated with distress. Two items containing contextual information were included as well, despite an insufficiently developed methodology. The paucity of clinical practice recommendations regarding the administration of drugs prescribed for distress is due to the fact that this pharmacological strategy seems to be unique to Québec. The update of Québec’s national medical protocol was therefore based on scientific data from drug product monographs, contextual data, and the perspectives of the stakeholders consulted. Updating Québec’s national medical protocol enabled us to clarify the clinical situation by stipulating that the person to whom the protocol is applied must present with sudden acute distress. In addition, the signs and symptoms for recognizing a distress situation have been revised. A panic state is now the first criterion for distress. It is associated with sudden major respiratory distress, sudden-onset or rapidly increasing intolerable pain, or a massive hemorrhage. As well, a section on the treatment principle has been added. Other, minor changes were made to the national medical protocol to harmonize the documents and their contents in line with the templates currently in use at INESSS. CONCLUSION: The update of this Québec’s national medical protocol on the administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care is based on clinical information from the literature, which has been enhanced with the perspectives of different experts and clinicians and with contextual information. Triangulating the data from these different sources enabled us to update the protocol in light of the best available clinical practices.
Authors' methods: INESSS updated, in accordance with its standards, the systematic review of clinical practice guidelines (CPGs), expert consensuses, consensus conference reports, guidance documents and all other items containing clinical recommendations concerning the administration of drugs prescribed via an individual prescription in the event of distress, namely, the trio consisting of a benzodiazepine, an opioid and an anticholinergic. The literature search was limited to items published between the publication, in 2016, of the national medical protocol and February 2020. The selected items concern palliative care patients 18 years of age and over who present with distress. The search parameters were the contraindications to the administrations of drugs prescribed for distress via an individual prescription, the health status assessment criteria, the physical examinations, the medication administration details, the contraindications, the adverse effects, the precautions and the drug interactions that one must know in order to administer the pharmacological treatment, and the follow-up required for this treatment. In addition, a manual literature search was conducted by consulting the websites of North American regulatory agencies, those of health technology assessment agencies, and those of government agencies and professional associations or bodies that deal with the topic of interest. The lists of references in the selected publications were examined for other relevant items. The data were analyzed from the perspective of contextualizing Québec practice, using mainly legislative, regulatory and organizational contextual elements specific to Québec, and the perspectives of the different stakeholders consulted.
Project Status: Completed
URL for protocol: https://www.inesss.qc.ca/thematiques/medicaments/protocoles-medicaux-nationaux-et-ordonnances-associees/soins-palliatifs-detresse.html
Year Published: 2020
URL for published report: https://www.inesss.qc.ca/thematiques/medicaments/protocoles-medicaux-nationaux-et-ordonnances-associees/soins-palliatifs-detresse.html
Requestor: Minister of Health
English language abstract: An English language summary is available
Publication Type: Other
- Palliative Care
- Drug Therapy
- Anti-Anxiety Agents
- Palliative Medicine
- Analgesics, Opioid
- Cholinergic Antagonists
- Terminal Care
- palliative care
Organisation Name: Institut national d'excellence en sante et en services sociaux
Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: L'Institut national d'excellence en santé et en services sociaux (INESSS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.